# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k061138   
B. Purpose for Submission: New Submission   
C. Measurand: C-Reactive Protein   
D. Type of Test: Quantitative immunoturbidimetric assay   
E. Applicant: Horiba ABX   
F. Proprietary and Established Names: ABX Pentra 400 : CRP CP

# G. Regulatory Information:

1. Regulation section: 21CFR Sec.- 866.5270-C-reactive protein immunological test system. 21CFR Sec.- 862.1150 Calibrator. 21CFR Sec.- 862.1660 Quality control material (assayed and unassayed).

2. Classification: II

3. Product code: DCK - C-Reactive Protein, Antigen, Antiserum, And Control JIS - Calibrator, Primary JJX - Single (specified) analyte controls (assayed and unassayed) JJY - Multi-analyte controls, all kinds (assayed and unassayed)

4. Panel: Immunology (82), Chemistry (75)

# H. Intended Use:

1. Intended use(s): See Indication(s) for use below:

2. Indication(s) for use: CRP reagent, with associated calibrators and controls, are intended for use on ABX PENTRA 400 Clinical Chemistry Analyzer to measure C-reactive Protein analyte.

The ABX PENTRA CRP Cal is a calibrator for use in the calibration of quantitative Horiba ABX PENTRA CRP CP method on Horiba ABX clinical chemistry analyzers.

The ABX PENTRA Low CRP Control is for use in quality control by monitoring accuracy and precision for the quantitative ABX PENTRA CRP CP method.

ABX PENTRA CRP CP reagent with associated calibrators and controls are for quantitative in vitro diagnostic determination of the C-reactive protein in human serum and plasma based on an immunoturbidimetric assay.

The ABX PENTRA Immuno I Control L/H is for use in quality control by monitoring accuracy and precision for CRP.

Measurement of C-reactive protein aids in evaluation of the amount of injury to body tissue.

3. Special conditions for use statement(s): The ABX PENTRA CRP reagent is for conventional CRP use only For professional use   
4. Special instrument requirements: ABX PENTRA 400 Clinical Chemistry Analyzer

I. Device Description:

The ABX Pentra CRP CP assay is ready-to-use, composed of a bi-reagent cassette, with $2 5 ~ \mathrm { m l }$ and $2 3 . 5 \mathrm { m l }$ compartments.

Reagent 1: Buffer solution:   
Glycine buffer solution   
Reagent 2: Latex suspension:   
$0 . 2 0 \%$ w/v suspension of latex particles sensitized with anti-CRP antibodies (rabbit)

The ABX PENTRA CRP Cal is a liquid human serum calibrator with chemical additives. It has 5 levels to be used for the calibration of the CRP assay. The assigned values are given on the calibrator vials. This calibrator is provided in five vials of 1 ml.

The ABX PENTRA Immuno I Control L/H is a lyophilized two-level quality control product consisting of human serum. The assigned values of the control components are given in control annex ensuring control of the appropriate HORIBA ABX methods on the ABX PENTRA 400 analyzer. Each level of control is provided in one vial of $3 ~ \mathrm { m l }$ .

The ABX PENTRA Low CRP Control is a liquid assayed control prepared by diluting CRP at low concentration in human serum. It has to be used for the quality control of low levels measured with the CRP assay. The assigned value is given in the control annex. This control is provided in four vials of $1 ~ \mathrm { m l }$ .

J. Substantial Equivalence Information:

1. Predicate device name(s): Kamiya, K-Assay C-Reactive Protein, Kamiya, K-Assay hs-CRP Controls   
2. Predicate 510(k) number(s): k023828, k022486   
3. Comparison with predicate:

<table><tr><td></td><td>Predica</td><td>Device :</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Device Name</td><td rowspan=1 colspan=1>K-ASSAY CRP (3)</td><td rowspan=1 colspan=1>ABX Pentra CRP CP</td></tr><tr><td rowspan=1 colspan=1>Method :</td><td rowspan=1 colspan=1>Latex-enhancedImmunoturbidimetric assay</td><td rowspan=1 colspan=1>Latex-enhancedImmunoturbidimetric assay</td></tr><tr><td rowspan=1 colspan=1>Specimen :</td><td rowspan=1 colspan=1>SerumPlasma</td><td rowspan=1 colspan=1>SerumPlasma</td></tr><tr><td rowspan=1 colspan=1>Component reagent matrices</td><td rowspan=1 colspan=1>Two reagent bottles:REAGENT 1: Buffer Reagent:Glycine buffer solution.REAGENT 2: Latex suspension:0.20% (w/v) suspension of latexparticles sensitized with anti-CRP antibodies (rabbit).</td><td rowspan=1 colspan=1>Bi-reagent cassette, ready to use:REAGENT 1 : Buffer solution:Glycine buffer solution.REAGENT 2 : Latex suspension:0.20% (w/v) suspension of latexparticles sensitized with anti-CRP antibodies (rabbit).</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Liquid</td><td rowspan=1 colspan=1>Liquid</td></tr><tr><td rowspan=1 colspan=1>Packaging</td><td rowspan=1 colspan=1>Two reagent bottles:REAGENT 1: 1 x 50 mlREAGENT 2: 1 x 50 ml</td><td rowspan=1 colspan=1>Bi-reagent cassette :REAGENT 1 : 25 mlREAGENT 2 : 23.5 ml</td></tr><tr><td rowspan=1 colspan=1>Performance data :Sample volumeDetection limitAccuracy and PrecisionAssay Linearity</td><td rowspan=1 colspan=1>On Hitachi 917: 3 μl/testStandard sensitivity: 0.1 mg/lHigh sensitivity: 0.05 mg/1Wide sensitivity : 0.2 mg/lCV Total &lt; 6.97%Standard sensitivity:0.1 mg/1 - 320 mg/lHigh sensitivity:0.05 mg/1 − 160 mg/1Wide sensitivity :0.2 mg/1 − 480 mg/1</td><td rowspan=1 colspan=1>4 μl/test0.09 mg/1 determined accordingto the CLSI (NCCLS), EP-17A protocolCV Total &lt; 7.04%Up to 160 mg/l</td></tr></table>

# ABX Pentra CRP Cal:

<table><tr><td colspan="1" rowspan="1">cYanmaGYellowb</td><td colspan="1" rowspan="1">Predicate Device (k023828):</td><td colspan="1" rowspan="1">Device :</td></tr><tr><td colspan="1" rowspan="1">Device Name</td><td colspan="1" rowspan="1">K-ASSAY CRP Calibrator Set E</td><td colspan="1" rowspan="1">ABX Pentra CRP Cal</td></tr><tr><td colspan="1" rowspan="1">Method :</td><td colspan="1" rowspan="1">Calibration of K-ASSAY CRP (3)on clinical chemistry analyzers</td><td colspan="1" rowspan="1">Calibration of ABX Pentra CRP CP onclinical chemistry analyzers</td></tr><tr><td colspan="1" rowspan="1">Componentmatrices</td><td colspan="1" rowspan="1">Vial (liquid)Human serum with chemical(preservative) and biologicaladditives</td><td colspan="1" rowspan="1">Vial (liquid)Human serum with chemical(preservative) and biological additives</td></tr><tr><td colspan="1" rowspan="1">Format</td><td colspan="1" rowspan="1">Liquid, ready-to-use</td><td colspan="1" rowspan="1">Liquid, ready-to-use</td></tr><tr><td colspan="1" rowspan="1">Packaging</td><td colspan="1" rowspan="1">Kit composed of :5 x 2 ml vial</td><td colspan="1" rowspan="1">Kit composed of :5 x 1 ml vial</td></tr><tr><td colspan="1" rowspan="1">Calibration values</td><td colspan="1" rowspan="1">- Traceable to IFCC CRM470.</td><td colspan="1" rowspan="1">- Determined using primary calibrationwith CRM n°470-CAP/IFCC, lot. 91/06-19.</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Predicate device (k022486):</td><td colspan="1" rowspan="1">Device :</td></tr><tr><td colspan="1" rowspan="1">Device Name</td><td colspan="1" rowspan="1">K-ASSAY hs-CRP Control Set</td><td colspan="1" rowspan="1">ABX Pentra Immuno I Control L/H</td></tr><tr><td colspan="1" rowspan="1">Method :</td><td colspan="1" rowspan="1">Single parameter control bymonitoring the performance of C-Reactive Proteinimmunoturbidimetric assays.</td><td colspan="1" rowspan="1">Quality control by monitoring accuracyand precision for the quantitative methodsas specified in the enclosed value sheet.</td></tr><tr><td colspan="1" rowspan="1">Componentmatrices</td><td colspan="1" rowspan="1">Vials (liquid)2 levelsPool of Human sera with chemicaladditives (preservatives)</td><td colspan="1" rowspan="1">Vials (lyophilizate)2 levelsPool of Human sera with chemicaladditives (preservatives)</td></tr><tr><td colspan="1" rowspan="1">Format</td><td colspan="1" rowspan="1">Liquid, ready-to-use</td><td colspan="1" rowspan="1">Lyophilizate (to reconstitute withdistilled/deionised water  not provided)</td></tr><tr><td colspan="1" rowspan="1">Packaging</td><td colspan="1" rowspan="1">Kit composed of :Level 1: 2 x 1 ml vial (blue cap)Level 2: 2 x 1 ml vial (red cap)</td><td colspan="1" rowspan="1">Kit composed of :2 x bottle, each with lyophilizate for 3 mlcontrol.</td></tr></table>

# ABX Pentra Low CRP Control:

<table><tr><td rowspan=1 colspan=1>cYanmaGellob</td><td rowspan=1 colspan=1>Predicate device (k022486):</td><td rowspan=1 colspan=1>Device :</td></tr><tr><td rowspan=1 colspan=1>Device Name</td><td rowspan=1 colspan=1>K-ASSAY hs-CRP Control Set</td><td rowspan=1 colspan=1>ABX Pentra Low CRP Control</td></tr><tr><td rowspan=1 colspan=1>Method :</td><td rowspan=1 colspan=1>Single parameter control bymonitoring the performance of C-Reactive Proteinimmunoturbidimetric assays.</td><td rowspan=1 colspan=1>Single parameter control by monitoring theperformances of C-Reactive Proteindetermination at low concentration.</td></tr><tr><td rowspan=1 colspan=1>Componentmatrices</td><td rowspan=1 colspan=1>Vials (liquid)2 levelsPool of Human sera with chemicaladditives (preservatives)</td><td rowspan=1 colspan=1>Vials (liquid)Human serum with chemical additives(preservatives)</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Liquid</td><td rowspan=1 colspan=1>Liquid</td></tr><tr><td rowspan=1 colspan=1>Packaging</td><td rowspan=1 colspan=1>Kit composed of :Level 1: 2 x 1 ml vial (blue cap)Level 2: 2 x 1 ml vial (red cap)</td><td rowspan=1 colspan=1>Kit composed of :4 x 1 ml vial</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI - Evaluation of Precision Performance of Clinical Chemistry Devices - EP05-A2 CLSI - Evaluation of the Linearity of Quantitative Analytical Methods - EP06-A CLSI - Method Comparison and Bias Estimation Using Patient Samples - EP09-A2 CLSI - Protocols for Determination of Limits of Detection and Limits of Quantitation - EP17-A

# L. Test Principle:

ABX Pentra CRP CP is a latex-enhanced immunoturbidimetric assay developed to measure CRP levels in serum and plasma samples for conventional CRP ranges.

When an antigen-antibody reaction occurs between CRP in a sample and anti-CRP antibody which has been sensitized to latex particles, agglutination results. This agglutination is detected as an absorbance change, with the magnitude of the change being proportional to the quantity of CRP in the sample. The actual concentration is then determined by interpolation from a calibration curve prepared from calibrators of known concentration.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: Within-run precision 5 specimens of very low, low, medium and high concentration and 3 controls were tested 20 times.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean valuemg/l</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Control specimen 1</td><td rowspan=1 colspan=1>8.54</td><td rowspan=1 colspan=1>0.74</td></tr><tr><td rowspan=1 colspan=1>Control specimen 2</td><td rowspan=1 colspan=1>22.16</td><td rowspan=1 colspan=1>1.08</td></tr><tr><td rowspan=1 colspan=1>Control specimen 3</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>3.07</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>0.86</td><td rowspan=1 colspan=1>4.15</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>8.13</td><td rowspan=1 colspan=1>1.55</td></tr><tr><td rowspan=1 colspan=1>Specimen 3</td><td rowspan=1 colspan=1>18.66</td><td rowspan=1 colspan=1>0.92</td></tr><tr><td rowspan=1 colspan=1>Specimen 4</td><td rowspan=1 colspan=1>46.83</td><td rowspan=1 colspan=1>1.02</td></tr><tr><td rowspan=1 colspan=1>Specimen 5</td><td rowspan=1 colspan=1>126.11</td><td rowspan=1 colspan=1>2.25</td></tr></table>

Total precision   
3 specimens of low, medium and high levels and 3 controls were tested in   
duplicate for 20 days (2 series per day)

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean valuemg/l</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Control specimen 1</td><td rowspan=1 colspan=1>8.46</td><td rowspan=1 colspan=1>4.31</td></tr><tr><td rowspan=1 colspan=1>Control specimen 2</td><td rowspan=1 colspan=1>21.88</td><td rowspan=1 colspan=1>2.17</td></tr><tr><td rowspan=1 colspan=1>Control specimen 3</td><td rowspan=1 colspan=1>1.23</td><td rowspan=1 colspan=1>5.57</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>62.25</td><td rowspan=1 colspan=1>2.32</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>124.14</td><td rowspan=1 colspan=1>2.92</td></tr><tr><td rowspan=1 colspan=1>Specimen 3</td><td rowspan=1 colspan=1>0.86</td><td rowspan=1 colspan=1>7.04</td></tr></table>

b. Linearity/assay reportable range:

The assay confirmed a measuring range from $1 . 0 \mathrm { m g / l }$ to $1 6 0 . 0 \mathrm { m g / l }$ , with an automatic post dilution up to $8 0 0 \mathrm { m g / l }$ . These claims were established by the method comparison study described in section 2 below and confirmed by linearity and post dilution studies. The linearity data submitted is summarized below:

<table><tr><td>Linearity test</td><td>Dilution</td><td>Theoretical concentration</td><td>mean</td></tr><tr><td rowspan="11">Lower range</td><td>0.0625</td><td>0.64</td><td>0.37</td></tr><tr><td>0.1250</td><td>1.29</td><td>0.93</td></tr><tr><td>0.2500</td><td>2.57</td><td>2.33</td></tr><tr><td>0.3750</td><td>3.86</td><td>3.68</td></tr><tr><td>0.5000</td><td>5.15</td><td>5.14</td></tr><tr><td>0.6250</td><td>6.43</td><td>6.42</td></tr><tr><td>0.7500</td><td>7.72</td><td>7.81</td></tr><tr><td>0.8750</td><td>9.01</td><td>9.04</td></tr><tr><td>0.9350</td><td>9.63</td><td>9.62</td></tr><tr><td>1.0000</td><td>10.30</td><td>10.30</td></tr><tr><td rowspan="11">Middle Range</td><td>0.10</td><td>5.12</td><td>5.14</td></tr><tr><td>0.20</td><td>10.24</td><td>10.71</td></tr><tr><td>0.30</td><td>15.35</td><td>15.83</td></tr><tr><td>0.40</td><td>20.47</td><td>20.37</td></tr><tr><td>0.50</td><td>25.59</td><td>25.67</td></tr><tr><td>0.60</td><td>30.71</td><td>30.78</td></tr><tr><td>0.70</td><td>35.82</td><td>35.68</td></tr><tr><td>0.80</td><td>40.94</td><td>40.97</td></tr><tr><td>0.90</td><td>46.06</td><td>46.06</td></tr><tr><td>1.00</td><td>51.18</td><td>51.18</td></tr><tr><td>0.125</td><td>20.00</td><td>20.33</td></tr><tr><td rowspan="8">Upper Range</td><td>0.250</td><td></td><td>39.3375</td></tr><tr><td></td><td>40.00</td><td></td></tr><tr><td>0.375 0.500</td><td>60.00</td><td>59.1625 82.7275</td></tr><tr><td>0.625</td><td>80.00 100.00</td><td>104.3625</td></tr><tr><td>0.750</td><td>120.00</td><td>124.7</td></tr><tr><td></td><td></td><td></td></tr><tr><td>0.875</td><td>140.00</td><td>142.735</td></tr><tr><td>0.938</td><td>150.00</td><td>152.875</td></tr><tr><td></td><td>1.000</td><td>160.00</td><td>ND</td></tr></table>

# Post-dilution Study

A post-dilution (factor $= 1 / 5$ ) will be initiated in cases of sample concentration above $1 6 0 \mathrm { m g / l }$ . For the samples tested the relative bias was lower than $+ / .$ - $10 \%$ over the range tested $( 1 6 0 - 7 2 6 \mathrm { m g / l } )$ .

# Hook effect

No high dose hook effect was observed up to a concentration of $2 0 0 \mathrm { m g / l }$ . A “Reaction Limit” alarm is calculated to flag samples which have an initial reaction speed higher than the highest calibrator point $1 6 0 \mathrm { m g / l } )$ ). In these cases a post-dilution will be preformed.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

# ABX Pentra CRP Cal

Traceability - Determined using primary calibration with CRM $\boldsymbol { \mathrm { n } } ^ { \circ } 4 7 0$ - CAP/IFCC, lot. 91/06-19. - The assigned values are indicated on each vial (5 levels with targeted values of 2.5, 10, 40, 80 and $1 6 0 \mathrm { m g / l }$ )

Closed stability: 12 months at $2 { \cdot } 1 0 ^ { \circ } \mathrm { C }$ Open stability: 3 months at $2 { \cdot } 1 0 ^ { \circ } \mathrm { C }$ Based on real time stability studies

# ABX Pentra Immuno I Control L/H

The assigned values specified are determined by calculating the mean value obtained from multiple determinations. The assigned values for both Low and High controls are lot-specific.

Closed stability: 24 months at $2 { \cdot } 1 0 ^ { \circ } \mathrm { C }$ Open stability after reconstitution: 2 weeks at $2 { \cdot } 1 0 ^ { \circ } \mathrm { C }$ 3 months at $- 2 0 ^ { \circ } \mathrm { C }$ Based on real time stability studies

# ABX Pentra Low CRP Control

The assigned values specified are determined by calculating the mean value obtained from multiple determinations. The assigned values for both Low and High controls are lot-specific.

Closed stability: 12 months at $2 { \cdot } 1 0 ^ { \circ } \mathrm { C }$ Open stability: 4 weeks at $2 { \cdot } 1 0 ^ { \circ } \mathrm { C }$ Based on real time stability studies

d. Detection limit:

The detection limit of this device (the lower range of measurement) was determined to be $1 . 0 \mathrm { m g / l }$ .

e. Analytical specificity:

Hemoglobin up to $4 8 5 \mathrm { m g / d l }$ , total bilirubin up to $1 6 . 9 \mathrm { m g / d l }$ , direct bilirubin up to $1 8 . 8 \mathrm { m g / d l }$ , and triglycerides (as Intralipid $\textsuperscript { \textregistered }$ , representative of lipemia) up to $6 1 2 . 5 \mathrm { m g / d l }$ do not interfere with CRP determination by this test.

Study method:

The above substances were added to the base serum at two different CRP concentration (approx $8 . 6 \mathrm { m g / l }$ and $2 7 . 3 6 \mathrm { m g / L } $ . The base serum with each substance was then serially diluted with the same base serum that was added saline instead of substance to adjust CRP concentration. The acceptance limit for non-interference was to be with-in $10 \%$ of the mean value of each level.

f. Assay cut-off: Not Applicable

2. Comparison studies:

a. Method comparison with predicate device: 190 patient samples (serum) were tested with the device and a commercial reagent according to the recommendations found in the CLSI (NCCLS), EP9- A2 protocol. Values ranged from 0.13 to $1 5 8 . 3 0 \mathrm { m g / l }$ .

The equation for the regression line obtained was: $\mathrm { Y } = 1 . 0 3 \mathrm { x } - 0 . 1 8$ with a correlation coefficient $\mathrm { r } ^ { 2 } = 0 . 9 9 7$ .

$b$ . Matrix comparison:

To demonstrate equivalence of CRP results in serum and Plasma HeparinLithium samples, comparison study was performed. Forty-nine (49) samples were evaluated on ABX Pentra 400 analyzer using ABX Pentra CRP CP reagent.

Serum verses Plasma equation for the regression line obtained was: $\mathrm { Y } = 0 . 9 8 3 . \mathrm { x } + 0 . 0 1 9 4$ with a correlation coefficient $\mathrm { r } ^ { 2 } = 0 . 9 9 9 2$

3. Clinical studies:

a. Clinical Sensitivity: Not Applicable

b. Clinical specificity: Not Applicable

c. Other clinical supportive data (when a. and b. are not applicable): Not Applicable

4. Clinical cut-off: Not Applicable

5. Expected values/Reference range: Adults (20-60 years) $< 5 \mathrm { m g / l }$ determined by referenced literature

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.